Ideally, this biomarker could be used additionally in decision-making for BRAF-mutated melanoma between ICI and BRAF or MEK inhibitor treatment, and contribute to the further optimization of personalized medicine in dermatological oncology. This evidence concerns the gene BRAF and melanoma.